Related Experiment Video
Updated: May 16, 2026
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA
Georgios Hatzichristodoulou1, Hubert Kübler, Hartwig Schwaibold
1Technische Universität München, Klinikum rechts der Isar, Department of Urology, Ismaninger Str. 22, 81675 Munich, Germany. georgios.hatzichris-todoulou@lrz.tum.de
Aim:
To compare nuclear matrix protein 22 expression by BladderChek® and ELISA, as urine-based assays for bladder cancer (BC) detection.
Patients And Methods:
Urine samples of 100 BC patients and 100 controls were analyzed. Comparative statistical evaluations were based on sensitivity and specificity.
Results:
Seventy-one patients had primary and 29 recurrent BC. The sensitivity of BladderChek® was significantly higher compared to ELISA in the overall cancer cohort and in patients with primary BC (p<0.0001 and p=0.0001, respectively). Both tests demonstrated significant correlation of sensitivities and tumor stage/grade for the overall cancer cohort and for patients with primary BC. Both tests had specificity values of 100% in healthy individuals. Specificity was 93% for BladderChek® and 99% for ELISA in patients with benign diseases (p=0.048).
Conclusion:
BladderChek® may be clinically more useful for BC detection. Due to high specificity, BladderChek® could be used for high-risk screening. However, due to its low sensitivity, BladderChek® cannot replace but only complement cystoscopy for BC detection.
